The Claim

Candesartan cilexetil (30 ppm), geranylgeranylacetone (600 ppm), and MIF098 (240 ppm) administered to UM-HET3 mice did not result in a statistically significant increase in lifespan in either male or female subjects at the doses tested.

Source: 17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
13score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Three drugs that were thought might help mice live longer were tested, but none of them actually made the mice live longer at the doses given.

See the scientific wording

Candesartan cilexetil, geranylgeranylacetone, and MIF098 did not significantly increase lifespan in either male or female UM-HET3 mice at the doses tested (30 ppm, 600 ppm, and 240 ppm respectively)

What the research says

1 study

  1. Study: 17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex

    The study tested the exact same three drugs (candesartan cilexetil, geranylgeranylacetone, and MIF098) on the same type of mice (UM-HET3) and found that none of them significantly extended lifespan in either males or females - exactly matching what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.